Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Clinical trial NCT03412877 · RECRUITING
Trial details
- NCT number
- NCT03412877
- Sponsor
- National Cancer Institute (NCI)
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-09-06
- Primary completion
- 2028-03-23
- Enrollment
- 285
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.